

## Errata

Název práce: Vliv drog na prenatální a postnatální vývoj člověka a modelových organizmů

Vedoucí bakalářské práce: RNDr. Lucie Hejnová, Ph.D.

Autor: Tereza Adamusová

## 5. Závěr

Problematika užívání opioidních látek v průběhu vývoje dítěte, popřípadě před početím dítěte, je velmi rozsáhlá. Nejde pouze o užívání drog, jako je například heroin ale i opioidních léčiv legálně předepisovaných lékaři. Současně se problematika týká i léčby závislosti pomocí substitučních látek jako je například metadon či buprenorfin. Dopad na postnatální vývoj má i podávání opioidních farmak přímo novorozencům.

Ke správné léčbě následků užívání drog v průběhu těhotenství je důležité porozumět jednotlivým procesům které vedou k následně pozorovaným odlišnostem mezi dětmi vystavenými opioidům a mezi dětmi, které žádné opioidní látky vystaveny nebyly. Procesy probíhající v plodech a novorozencích se mohou lišit oproti procesům u dospělých jedinců, což je důležitý aspekt především při studiu novorozeneckého abstinčního syndromu. Problematika prožívání abstinčních příznaků u novorozenců je velmi rozsáhlá a hlubší porozumění by mohlo mít významný pozitivní dopad na budoucí léčbu.

Vývojové defekty, které se často u novorozenců vyskytují jsou srdeční vady, nízká porodní váha, dechová nedostatečnost, poruchy vývoje vidění a výskyt předčasných porodů. Časté jsou také poškození nervové tkáně. Ve většině případů, u kterých nedošlo k rozsáhlým malformacím nicméně v pozdějším věku nepozorujeme výrazný rozdíl v kognitivních schopnostech mezi zdravými dětmi a dětmi vystavenými droze či léčivu. Při hodnocení IQ byl prokázán mnohem výraznější vliv prostředí, ve kterém dítě vyrůstá než vliv přítomnosti opioidní látky v průběhu vývoje.

Dále by bylo vhodné hlouběji studovat vliv užívání různých substitučních léčiv, mimo nejčastěji užívaný metadon a buprenorfin. Kombinace v průběhu léčby s jinými substitučními látkami, například klonidinem, by mohla urychlit léčbu abstinčních příznaků novorozenců a zlepšit tak přetrvávající následky z dlouhodobého užívání opioidů u novorozenců.

## 6. Literatura

- Abu Jawdeh E. G., Westgate P. M., Pan A., Stacy A. L., Mamilla D., Gabrani A., Patwardhan A., Bada H. S., Giannone P. 2017. "Prenatal Opioid Exposure and Intermittent Hypoxemia in Preterm Infants." *Frontiers in Pediatrics* 12(5): 253-64.
- Al-Hasani R., and Bruchas M. R. 2011. "Molecular Mechanisms of Opioid Receptor-Dependent Signalling and Behaviour." *Anesthesiology* 115(6): 1363–81.
- Albright B., de la Torre L., Skipper B., Price S., Abbott P., Rayburn W. 2011. "Changes in Methadone Maintenance Therapy during and after Pregnancy." *Journal of substance abuse treatment* 41(4): 347–53.
- Anand K. J., Hall R. W., Desai N., Shephard B., Bergqvist L. L., Young T. E., Boyle E. M., Carbajal R., Bhutani V. K., Moore M. B., Kronsber S. S., Barton B.A. 2004 "The Effect of Morphine Analgesia in Ventilated Preterm Neonates: Primary Outcomes from the NEOPAIN Randomised Trial." *The Lancet* 22(5) 1673-82.
- Anderson B. J., Holford N. H. G., Hall R. W., Young T., Shephard B., Desai N. S., Barton B. A. 2008. "Morphine Pharmacokinetics and Pharmacodynamics in Preterm and Term Neonates: Secondary Results from the NEOPAIN Trial." *British Journal of Anaesthesia* 101(5): 680–89.
- Bajic D., Commons K. G., and Soriano S. G. 2013. "Morphine-Enhanced Apoptosis in Selective Brain Regions of Neonatal Rats." *International Journal of Developmental Neuroscience* 31(4): 258–66.
- Baldacchino A., Arbuckle K., Petrie D. J., and McCowan C. 2014. "Neurobehavioral Consequences of Chronic Intrauterine Opioid Exposure in Infants and Preschool Children: A Systematic Review and Meta-Analysis." *BMC Psychiatry* 14(1): 104–16 rev.
- Baneshi R. E. M., Mirkamandar E., Maghsoudi S., Rastegari A., 2011. "A Comparison between APGAR Scores and Birth Weight in Infants of Addicted and Non-Addicted Mothers." *Addiction and Health* 3(1): 61–67.
- Broussard C. S., Rasmussen S. A., Reefhuis J., Friedman J., Jann M. W., Riehle-Colarusso T., Honein M. A. 2011. "Maternal Treatment with Opioid Analgesics and Risk for Birth Defects." *American Journal of Obstetrics and Gynecology* 204(4): 314-27.

- Carrupt P. A., Testa B., Bechalany A., El Tayar N., Descas P., Perrissoud D. 1991. "Morphine 6-Glucuronide and Morphine 3-Glucuronid as Molecular Chamaleons with Unexpected Lipophilicity." *Journal of Medicinal Chemistry* 34(4): 1272–75.
- Choonara I. A., McKay P., Hain R., Rane A. 1989. "Morphine Metabolism in Children." *British Journal of Clinical Pharmacology* 28(5): 599–604.
- Coffman B. L., King C. D., Rios D. R., and Tephly T. R. 1998. "THE GLUCURONIDATION OF OPIOIDS, OTHER XENOBIOTICS, AND ANDROGENS BY HUMAN UGT2B7Y(268) AND UGT2B7H." *Drug Metabolism and Disposition* 26(1): 73–77.
- Coyle M. G., Salisbury A. L., Lester B. M., Jones H. E., Lin H., Graf-Rohrmeister K., Fischer G. 2012. "Neonatal Neurobehavior Effects Following Buprenorphine versus Methadone Exposure." *Addiction* 107(1): 63–73.
- Claude D., Rousselle C., Pollack G. M., and Scherrmann J. M. 2000. "Development of an *In Situ* Mouse Brain Perfusion Model and Its Application to *Mdr1a* P-Glycoprotein-Deficient Mice." *Journal of Cerebral Blood Flow and Metabolism* 20(2): 381–86.
- Dafang W., Kang Y. S., Bickel U., and Pardridge W. M., 1997. "Short Communication Blood-Brain Barrier Permeability to Morphine-6-Glucuronide Is Markedly Reduced." *Pharmacology* 25(6): 768–71.
- Decker G., Wanner G., Zenk M. H., and Lottspeich F. 2000. "Characterization of Proteins in Latex of the Opium Poppy (*Papaver Somniferum*) Using Two-Dimensional Gel Electrophoresis and Microsequencing." *Electrophoresis* 21(16): 3500-16.
- Di Y. M., Chan E., Wei M. Q., Liu J., Zhou S. 2009. "Prediction of Deleterious Non-Synonymous Single-Nucleotide Polymorphisms of Human Uridine Diphosphate Glucuronosyltransferase Genes." *The AAPS Journal* 11(3): 469–80.
- Fall H. D., Vijayakumar M., Barker D. J. P., Osmond C., Duggleby S. 1993. "Weight in Infancy and Prevalence of Coronary Heart Disease in Adult Life." *BMJ Journal* 310(69): 17-9.
- Fatemeh K., Vahdani F. G., and Latifi S., 2016. "The Effects of Maternal Opium Abuse on Fetal Heart Rate Using Non-Stress Test." *Iranian Journal of Medical Sciences* 41(6): 479–85.
- Finnegan L. P., Hagan T., and Kaltenbach K. A. 1991. "Scientific Foundation of Clinical Practice: Opiate Use in Pregnant Women." *The Bulletin of New York Academy of Medicine* 67(3): 223–39.

- Ghafari S., Roshandel D., Golalipour J. F. 2011. "Effect of Intrauterine Morphine Sulfate Exposure on Cerebellar Histomorphological Changes in Neonatal Mice." *Folia Neuropathologica* 49(4): 328–34.
- Gherzi-Egea J. F., Leninger-Muller B., Suleman G., Siest G., Minn A. 1994. "Localization of Drug-Metabolizing Enzyme Activities to Blood-Brain Interfaces and Circumventricular Organs." *Journal of Neurochemistry* 62(3): 1089–96.
- De Gregori S., De Gregori M., Ranzani G. N., Allegri M., Minella C., Regazzi M. 2012. "Morphine Metabolism, Transport and Brain Disposition." *Metabolic Brain Disease* 27(1): 1–5.
- Guo X., Spencer J. W., Hickey J. E., Better W. E., Herning R. 1993. "Cognitive Brain Potentials in Boys Exposed to Opiates in Utero." *NIDA Research Monograph Series* 19(4): 429-41.
- Hall E. J., and Sykes N. P. 2004. "Analgesia for Patients with Advanced Disease: I." *Postgraduate Medical Journal* 80(941): 148–54 rev.
- Hauser K. F., Gurwell J. A., and Turbek C. S., 2009. "Morphine Inhibits Purkinje Cell Survival and Dendritic Differentiation in Organotypic Cultures of the Mouse Cerebellum." *Experimental Neurology* 6(1): 247–53.
- Heller N. A., Logan B. A., Morrison D. G., Paul J. A., Brown M. S., Hazes M. J. 2015. "Neonatal Abstinence Syndrome: Neurobehavior at 6 Weeks of Age in Infants With or Without Pharmacological Treatment for Withdrawal." *Anal Chem.* 25(4): 368–79.
- Housová J., Wilczek H., Křemen J., Křížová J., Haluzík M. 2005. "Adipocyte-Derived Hormones in Heroin Addicts: The Influence of Methadone Maintenance Treatment." *Physiological Research* 54(1): 73–78.
- International Narcotics Control Board Report 2010. 2011 1-210.
- Jansson L. M., Dipietro J. A., Vele M., Elko A., William E., Milio L., Grady K. O., Jones H. E. 2012. "Fetal Neurobehavioral Effects of Exposure to Methadone or Buprenorphine." *Neurotoxicology and Teratology* 33(2): 240–43.
- Kaltenbach K., and Finnegan L. P., 1987. "Perinatal and Developmental Outcome of Infants Exposed to Methadone In-Utero." *Neurotoxicology and Teratology* 9(4): 311–13.
- Kandall S. R., Albin S., Dreyer E., Comstock M., Lowinson J. 1975. "Differential Effects of Heroin and Methadone on Birth Weights." *Addictive diseases* 2(1): 347–55.
- Katselou M., Papoutsis I., Nikolaou P., Spiliopoulou C., Athanaselis S. 2014. "A 'Krokodil' Emerges from the Murky Waters of Addiction. Abuse Trends of an Old Drug." *Life Sciences* 102(2): 81–87.

- Knøsgaard K. R., Foster D. J. R., Kreilgaard M., Sverrisdóttir E., Upton R. N., Van den Anker J.N. 2016. "Pharmacokinetic Models of Morphine and Its Metabolites in Neonates: Systemic Comparisons of Models from the Literature, and Development of a New Meta-Model." *European Journal of Pharmaceutical Sciences*. 92: 117–30.
- Lithell H., Mckeigue P. M., Berglund L., Mohsen R., Lithell U., Leon D. A. 1996. "Relation of Size at Birth to Non-Insulin Dependent Diabetes and Insulin Concentrations in Men Aged 50-60 Years." *BMJ Journal* 312(2): 406–10.
- Mack K. A., Jones M. C., and Paulozzi L. J. 2013. "Vital Signs: Overdoses of Prescription Opioid Pain Relievers and Other Drugs Among Women — United States, 1999–2010." *Morbidity and mortality weekly report* 62(26): 537–42.
- Malek A., Obrist C., Wenzinger S., and von Mandach U. 2009. "The Impact of Cocaine and Heroin on the Placental Transfer of Methadone." *Reproductive Biology and Endocrinology* 7: 1–9.
- Mao J., Sung B., Ru-rong J., and Lim G. 2002. "Neuronal Apoptosis Associated with Morphine Tolerance : Evidence for an Opioid-Induced Neurotoxic Mechanism." *Journal of Neurosciences* 22(17): 7650–61.
- Mars S., Bourgois P., Karandinos G., Montero F., Ciccarone D., 2017. "The Textures of Heroin: User Perspectives on 'Black Tar' and Powder." *Journal of psychoactive drugs* 48(4): 39–46.
- McCaffrey G., and Davis T. P. 2012. "Physiology and Pathophysiology of the Blood-Brain Barrier: P-Glycoprotein and Occludin Trafficking as Therapeutic Targets to Optimize Central Nervous System Drug Delivery." *Journal of investigative medicine* 60(8): 1131–40.
- Mulvihill A. O., Cackett P. D., George N. D., and Fleck B. W. 2007. "Nystagmus Secondary to Drug Exposure in Utero." *British Journal of Ophthalmology* 91(5): 613–15.
- Navaneethakrishnan R., Tutty S., Sinha C., and Lindow S. W. 2006. "The Effect of Maternal Methadone Use on the Fetal Heart Pattern: A Computerised CTG Analysis." *Journal of Obstetrics and Gynaecology* 113(8): 948–50.
- Nettleton R. T., Wallisch M., and Olsen G. D. 2009. "Respiratory Effects of Chronic in Utero Methadone and Morphine Exposure in the Neonatal Guinea Pig." *Neurotoxicology and Teratology* 6(5): 247–53 rev.

- Nutt D., King L. A., Saulsbury W., and Blakemore C. 2007. "Development of a Rational Scale to Assess the Harm of Drugs of Potential Misuse." *The Lancet* 369: 1047–53.
- Nygaard E., Slinning K., Moe V., Due-Tønnessen P., Fjell A., Walhovd K. B. "Neuroanatomical Characteristics of Youths with Prenatal Opioid and Poly-Drug Exposure." *Neurotoxicology and Teratology* 68(12): 13–26.
- Nygaard E., Vibeke M., Slinning K., and Walhovd K. B. 2015. "Longitudinal Cognitive Development of Children Born to Mothers with Opioid and Polysubstance Use." *Pediatric Research* 78(3): 330–35.
- O'Brien C. P., 2008. "Evidence-Based Treatments of Addiction." *Philosophical Transactions of the Royal Society B: Biological Sciences* 363(1507): 3277–86 rev.
- Ornoy A., Michailevskaya V., Lukashov I., and Harel S., 1996. "The Developmental Outcome of Children Born to Heroin- Dependent Mothers , Raised at Home or Adopted ." *Child Abuse and Neglect* 20(5): 358-96.
- Pacifici G. M., Sawe J., Kager L., and Rane A., 1982. "Morphine Glucuronidation in Human Fetal and Adult Liver." *European Journal of Clinical Pharmacology* 22(6): 553–58.
- Pacifici G. M. 2016. "Metabolism and Pharmacokinetics of Morphine in Neonates: A Review." *Clinics* 71(8): 474–80 rev.
- Parikh R., Hussain T., Holder G., Bhojar A., Ewer A. 2011. "Maternal Methadone Therapy Increases QT Interval in Newborn Infants." *BJM journal* 96(2): 141-3.
- Park E., Meltzer-Brody S., and Suzuki J. 2015. "Evaluation and Management of Opioid Dependence in Pregnancy." *Psychosomatics*. 53(5): 424–32 rev.
- Pasternak G. W., and Pan Y. X. 2013. "Mu Opioids and Their Receptors: Evolution of a Concept." *Pharmacological Reviews* 65(4): 1257–1317 rev.
- Patrick S. W., Davis M. M., Lehman C. U., and Cooper W. O. 2015. "Increasing Incidence and Geographic Distribution of Neonatal Abstinence Syndrome: United States 2009-2012." *Journal of Perinatology* 35(8): 650–55.
- Paulozzi L. J., Jones C., Mack K., and Rudd R., 2011. "Vital Signs: Overdoses of Prescription Opioid Pain Relievers --- United States, 1999--2008." *Morbidity and Mortality Weekly Report* 60(43): 1487–92.

- Pucci F., Garris C., Lai C. P., Newton A., Engblom C., Alvarez D., Sprachman M., Evavold C., Magnuson A., Andrian U., Glatz K., Breakefield X. O., Mempel T. R., Weissleder R., Pittet M. J., 2016. "Maternal Use of Opioids During Pregnancy and Congenital Malformations: A Systematic Review." *Pediatrics* 139(6): 242–77 rev.
- Reddy U. M., Davis J. M., Zhaoxia R., Greene. F. M. 2015. "Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development" *Journal of Obstetricians and Gynecology* 130(1): 10-28.
- Sahraei H., Rostamkhani F., Tekieh E., Dehghani L., Poorazizi E., Meamar R., Kazemi M. 2013. "Identification of Morphine Accumulation in the Rat Embryo Central Nervous System: A C14-Morphine Administration Study." *International Journal of Preventive Medicine* 4: 222–28.
- Sandeep C., Destrebecq D., Kagawa A., Kunnen S., Pichon T., Nathwani A., Pietschmann T., Rhomberg W., Saadeddin A., Thomas J., Tullis M. 2004. "Programme U.N.I.D.C. World Drug Report." *Oxford University Press* 1: 1-210 rev.
- Schaefer C. P., Tome M. E. and Davis. T. P. 2017. "The Opioid Epidemic: A Central Role for the Blood Brain Barrier in Opioid Analgesia and Abuse." *Fluids and Barriers of the CNS* 14(1): 1–11 rev.
- Schiff P. L. Jr. 2002. "Opium and Its Alkaloids." *American Journal of Pharmaceutical Education* 66(2): 186–94 rev.
- Shuxian H., Sheng W. S., Lokensgard J. R., and Peterson P. K., 2002. "Morphine Induces Apoptosis of Human Microglia and Neurons." *Neuropharmacology* 42(1): 829–36.
- Smith M. T. 2000. "Neuroexcitatory Effects of Morphine and Hydromorphone: Evidence Implicating the 3-Glucuronide Metabolites." *Clinical and Experimental Pharmacology and Physiology* 27(7): 524–28.
- Steinhorn R., McPherson C., Anderson P. J., and Neil J. 2015. "Neonatal Morphine Exposure in Very Preterm Infants – Cerebral Development and Outcomes." *Journal of Pediatrics* 166(5): 1200–7.
- Štenclová A., 2010. "Opium - Chemické Složení, Využití a Možnosti Zneužívání" *Univerzita Karlova v Praze Farmaceutická fakulta v Hradci Králové* rev.
- Twycross R. G. 1973. "Stumbling Blocks in the Study of Diamorphine." *Postgraduate Medical Journal* 49(571): 309–13 rev.

- Velez M. L, Jansson L. M., Schroeder J., and Williams E., 2010. "Prenatal Methadone Exposure and Neonatal Neurobehavioral Functioning." *Journal of Pediatric Research* 66(6): 704–9.
- Vuong C., Van Uum S. H. M., O'Dell L. E., Lutfy K., Friedman T. C. 2010. "The Effects of Opioids and Opioid Analogs on Animal and Human Endocrine Systems." *Endocrine Reviews* 31(1): 98–132 rev.
- Weid M., Ziegler J., and Kutchan T. M. 2004. "The Roles of Latex and the Vascular Bundle in Morphine Biosynthesis in the Opium Poppy, *Papaver Somniferum*." *Proceedings of the National Academy of Sciences of the United States of America* 101(38): 13957–62.
- Welle-Strand G. K., Skurtveit S., Waal H., Ravndal E., Bakstad B., Jones H. E., Bjarko L. 2013. "Neonatal Outcomes Following in Utero Exposure to Methadone or Buprenorphine: A National Cohort Study of Opioid-Agonist Treatment of Pregnant Women in Norway from 1996 to 2009." *Drug and alcohol dependence* 127(1): 200–6.
- Wittert, G., Pyle D., and Hope P., 1996. "Tissue Distribution of Opioid Receptor Gene Expression in the Rat." *Biochemical and Biophysical Research Communications*. 218(3): 877–81.
- Yazdy M., Mitchell A., Tinker S., Parker S., Werler M. 2015. "Periconceptional Use of Opioids and the Risk of Neural Tube Defects." *Journal of Obstetrics and Gynecology* 122(4): 838–44.
- Young A. M, Havens J. A., Leukefeld C. G. 2010. "Route of Administration for Illicit Prescription Opioids: A Comparison of Rural and Urban Drug Users." *Harm Reduction Journal* 7(1): 24–31.
- Zwicker J. G., Miller S. P, Grunau R. E, Brant R., Studholme C., Liu M., Poskitt K. J. Stiver, M. L., Wy E. 2017. "Smaller Cerebellar Growth and Poorer Neurodevelopmental Outcomes in Very Preterm Infants Exposed to Morphine." *Journal of Pediatrics* 62(5): 81–87.